HealthcareServices

Live Attenuated Polio Vaccine Global Forecast: Market to Scale Up to $2.85 Billion by 2030 at 7.6% CAGR

February 26, 2026February 26, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the live attenuated polio vaccine market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Live Attenuated Polio Vaccine Market by the end of 2030?

The market for live attenuated polio vaccines has demonstrated robust expansion recently. Its size is projected to increase from $1.98 billion in 2025 to $2.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. Historically, this expansion has stemmed from global campaigns to eradicate polio, the widespread acceptance of oral polio vaccines, robust government-led immunization efforts, early triumphs in decreasing polio transmission, and assistance from international health organizations.

The live attenuated polio vaccine market is anticipated to show significant expansion in the next few years. It is projected to reach $2.85 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.6%. The increase during the forecast period can be attributed to persistent eradication efforts in remaining endemic areas, a heightened focus on preventing outbreaks, extending vaccination coverage to underserved populations, increased funding for public health immunization initiatives, and a rising emphasis on vaccine accessibility and affordability. Prominent trends for the forecast period include the continued use of oral polio vaccines in mass immunization campaigns, a strong focus on community-level immunity and transmission control, sustained demand in polio-endemic and high-risk regions, the integration of LAPV into national immunization programs, and an emphasis on achieving long-lasting immunity in pediatric vaccination.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24280&type=smp

What Drivers Are Shaping Future Opportunities In The Live Attenuated Polio Vaccine Market?

The future expansion of immunization programs is anticipated to drive the growth of the live attenuated polio vaccine market. Immunization programs are defined as structured initiatives by governments, health bodies, or other entities aimed at delivering vaccines to populations to avert the spread of infectious diseases. This expansion primarily stems from a heightened global understanding of the significance of disease prevention, coupled with robust backing from governments, international health organizations, and financial sponsors. These programs bolster the live attenuated polio vaccine (LAPV) by guaranteeing extensive distribution, secure administration, and broad coverage, which helps establish herd immunity, prevent viral transmission, and contribute to worldwide polio eradication. For example, in May 2025, data from the UK Health Security Agency, a UK government body, indicated that during the 2023–2024 season, a school-based initiative in England, targeting all children aged 4 to 16 (Reception to Year 11), resulted in 52.2% of eligible children from Reception to Year 9 (3,498,576 out of 6,708,016) receiving the vaccine. This figure represents a slight increase from the 51.9% coverage (3,502,566 out of 6,747,523) observed in the 2022–2023 season. Consequently, the expansion of immunization programs is indeed fostering the growth of the live attenuated polio vaccine market.

Which Segments Are Gaining Traction In The Live Attenuated Polio Vaccine Market?

The live attenuated polio vaccine market covered in this report is segmented –

1) By Vaccine Type: Monovalent, Bivalent, Trivalent

2) By Age Group: Infants (0-1 years), Children (1-5 years)

3) By End-User: Clinics, Public Health Agencies, Other End-Users

Subsegments:

1) By Monovalent: mOPV1 For Serotype 1

2) By Bivalent: Type 1, Type 3

3) By Trivalent: Poliovirus Type 1, Poliovirus Type 2, Poliovirus Type 3

Which Trends Are Shaping Activity Within The Live Attenuated Polio Vaccine Market?

Key companies in the live attenuated polio vaccine market are concentrating on securing regulatory authorizations to ensure their vaccines fulfill the safety and effectiveness benchmarks mandated by health organizations worldwide. Regulatory approvals represent the official endorsement granted by governmental health agencies or oversight bodies, permitting a product, like a vaccine, to be commercialized, sold, and administered within a particular region or country. For example, in July 2024, Biological E, an Indian pharmaceutical and biologics firm, obtained World Health Organization (WHO) approval for its novel oral polio vaccine type 2 (nOPV2), which is a new generation live, attenuated oral vaccine crafted to resolve difficulties associated with existing oral polio vaccines. This advanced vaccine is intended to combat outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2) more proficiently than its previous iterations. nOPV2 is developed with superior genetic stability, mitigating the likelihood of the vaccine virus reverting to a virulent form, which has been a point of concern with older vaccines.

Who Are The Primary Competitors In The Global Live Attenuated Polio Vaccine Market?

Major companies operating in the live attenuated polio vaccine market are Sanofi Pasteur, Serum Institute of India Pvt. Ltd., Biological E Limited, Indian Immunologicals Limited, Bharat Biotech International Limited, Panacea Biotec, Haffkine Biopharmaceutical, Bio Farma, Bilthoven Bio, Vabiotech, Sinovac Biotech Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Liaoning Cheng Da Biotechnology Co. Ltd., LG Chem Ltd., Chumakov Federal Scientific Center, Institute of Poliomyelitis and Viral Encephalitides, Statens Serum Institut, Federal State Unitary Enterprise Microgen, Pasteur Institute of Iran, Institut Pasteur de Dakar

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/live-attenuated-polio-vaccine-global-market-report

Which Regions Are Poised For Strategic Growth In The Live Attenuated Polio Vaccine Market?

North America was the largest region in the live attenuated polio vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated polio vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Live Attenuated Polio Vaccine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24280&type=smp

Browse Through More Reports Similar to the Global Live Attenuated Polio Vaccine Market 2026, By The Business Research Company

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Conjugate Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

Inactivated Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795